▶ PEG-MGF · SUBTOPIC · DOSING LITERATURE
PEG-MGF Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of PEG-MGF. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for PEG-MGF reports the following route(s) of administration: Subcutaneous (research), Intramuscular (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of PEG-MGF.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for PEG-MGF of approximately Several days (PEGylated vs. <30 minutes for native MGF). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of PEG-MGF. Refer to the original publication for full protocol detail.
- Goldspink G, Yang SY (2002) reports the PEG-MGF protocol used in Mechano growth factor and a method for improvement of muscle, published in J Musculoskelet Neuronal Interact. See the source for the protocol-level dose range, frequency, and duration. link
- Hill M, Wernig A, Goldspink G (2003) reports the PEG-MGF protocol used in Muscle satellite (stem) cell activation during local tissue injury and repair, published in J Anat. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is PEG-MGF?
PEG-MGF is a PEGylated form of mechano growth factor (MGF), the IGF-1Ec splice variant produced locally in muscle in response to mechanical loading or injury. PEGylation extends the otherwise sub-30-minute half-life to support practical research dosing.
▶ PEG-MGF vs IGF-1 LR3 · which is better?
Different mechanisms. IGF-1 LR3 is a systemic IGF-1R agonist that drives whole-body anabolism. PEG-MGF acts more locally on satellite-cell activation at the site of injection or injury and does not produce the same systemic IGF-1R signaling. Research protocols select between them based on the local-vs-systemic research design.
▶ What is the half-life of PEG-MGF?
Several days, depending on the PEG conjugate. Native MGF has a half-life under 30 minutes; the PEGylation strategy extends systemic exposure to support practical dosing in animal-model research.
▶ How is PEG-MGF dosed in research?
Animal-model and community-reported research protocols use 200-1000 mcg per administration, subcutaneous or intramuscular at the target muscle, post-workout in resistance-training research. No human dose is recommended by this wiki.
▶ Why is PEG-MGF injected locally?
MGF is the local IGF-1 variant produced in response to muscle loading. Local intramuscular injection at the target muscle group is the standard research approach to maximize satellite-cell activation at that specific site rather than driving systemic IGF-1R signaling.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · -20 °C 24 months
Reconstituted · 2-8 °C, 14-28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. Research-use only.
WADA · Prohibited at all times under WADA Section S2 (Growth Factors sub-category).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25